

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Jinhai Medical Technology Limited**

**今海醫療科技股份有限公司**

*(Incorporated in the Cayman Islands with members' limited liability)*

**(Stock Code: 2225)**

### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNUAL REPORT 2024**

Reference is made to the annual report of Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year 2024 (the “**Annual Report**”), the announcements of the Company dated 9 April 2024 (the “**Major Transaction Announcements**”) in relation to the Property Acquisition and Share Acquisition, the circular of the Company dated 24 June 2024 (the “**Major Transactions Circular**”) in relation to the Property Acquisition and the Share Acquisition.

Reference is also made to the circular of the Company dated 8 December 2023, the share option scheme published by the Company dated 8 December 2023 (the “**Share Option Scheme**”) and the poll results announcement of the Company dated 29 December 2023 in relation to the adoption of the Share Option Scheme, and the announcement of the Company dated 9 January 2024, the circular of the Company dated 29 January 2024 and the poll results announcement of the Company dated 19 February 2024 in relation to the grant of options under Share Option Scheme.

Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Annual Report, the Major Transaction Announcements, the Major Transactions Circular and Share Option Scheme.

In addition to the information provided in the Annual Report, the board of directors (the “**Board**”) would like to provide the following supplementary information to the Annual Report, and the Annual Report shall be read in conjunction with the information below.

#### **REMEDIAL MEASURES**

Paragraph D.2.4 of Appendix C1 of the Listing Rules provides that the Board has the overall responsibility to maintain sound and effective risk management and internal control systems for the Group, in particular the process used to review the effectiveness of the risk management and internal control systems and to resolve material internal control defects.

During the Reporting Period, a series of risk management and internal control measures which were put into place by the Board to prevent the occurrence of similar non-compliance incidents in the future are set out below:

1. the Company has enhanced its internal control policy and system on notifiable transaction to strengthen its supervision on compliance with Chapter 14 of the Listing Rules, in particular in relation to the calculation of applicable percentage ratios at the time of each transaction;
2. the Company has conducted an internal training session in July 2024 to the Directors and management team members of the Group to explain the relevant Listing Rules requirements for notifiable transactions, and to emphasize the importance of working out accurately the size tests of each transaction prior to its execution;
3. the Company has hired a staff with professional qualification, namely, a member of Hong Kong Institute of Certified Public Accountants to oversee the transactions and the calculation of the relevant size tests in the future; and
4. the Company has sought external legal and other professional advice as to all proposed transactions to ensure compliance with the Listing Rules.

With the implementation of the remedial measures and internal control measure above, the Board is of the view that such measures will be able to ensure continued compliance with Chapter 14 of the Listing Rules and prevent the occurrence of similar incidents in the future.

## **SHARE OPTION SCHEME**

The Board also wishes to advise and supplement pursuant to Rule 17.07(2) of the Listing Rules that the number of options available for grant under the Scheme Mandate Limit and Service Provider Sublimit at the beginning and the end of the financial year 2024 are set out below:

<b>Type</b>	<b>As at 1 January 2024 (Note)</b>	<b>As at 31 December 2024</b>
Scheme Mandate Limit	517,000,000	0
Service Provider Sublimit	51,700,000	0

*Note:* the numbers were adjusted with reference to the share subdivision of the Company having taken effect on 10 December 2024.

For details of the options granted under Share Option Scheme, please refer to the announcement of the Company dated 9 January 2024, the circular of the Company dated 29 January 2024 and the poll results announcement of the Company dated 19 February 2024.

For details of the share subdivision of the Company, please refer to the announcement of the Company date 1 November 2024, circular of the Company dated 22 November 2024 and the poll results announcement of the Company dated 10 December 2024.

The above supplementary information does not affect other information contained in the Annual Report. Save as disclosed above, all other information in the Annual Report remains unchanged.

By Order of the Board  
**Jinhai Medical Technology Limited**  
**Chen Guobao**  
*Chairman of the Board and executive Director*

Hong Kong, 7 July 2025

*As at the date of this announcement, the Board comprises eight Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping; two are non-executive Directors, namely Mr. Jiang Jiangyu and Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.*